Archrock Partners, L.P., together with its subsidiaries, provides natural gas contract operations services to customers in the United States. The company's contract operations services primarily include designing, sourcing, owning, installing, operating, servicing, repairing, and maintaining equipment to provide natural gas compression services to its customers. It serves companies engaged in various aspects of the oil and natural gas industry, including oil and natural gas producers, processors, gatherers, transporters, and storage providers. The company markets its services through sales and field service personnel. Archrock General Partner, L.P. operates as the general partner of the company. The company was formerly known as Exterran Partners, L.P. and changed its name to Archrock Partners, L.P. in November 2015. Archrock Partners, L.P. was founded in 2006 and is based in Houston, Texas.
Company Website : http://www.archrock.com/aplp
Address : 9807 Katy Freeway, Suite 100 77024,Houston,USA
Fiscal Year End : December
Currency: USD
Country : USA
Beta : 1.98
52 Week High : 16.17
Short Ratio : 3.52
52 Week Low : 10.58
Shorted Shares : 335,159
200 Day Moving Average : 13.00
Shorted Shares Previous Month : 316,707
50 Day Moving Average : 14.91
| Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
|---|---|---|---|---|---|
| LGCY | Legacy Reserves Inc |
N/A |
USD61,525,874.67B | 1.10 | 5.30 |
| FTD | FTD Companies, Inc |
N/A |
USD28,725,913.80B | N/A | N/A |
| KEYW | The KeyW Holding Corporation |
N/A |
USD24,651,104.38B | 166.80 | 24.48 |
| SNHY | Helios Technologies, Inc |
N/A |
USD17,848,852.22B | 1,000,000.00 | N/A |
| QTNA | Quantenna Communications, Inc |
N/A |
USD8,997,243.52B | 175.07 | 79.98 |
| INSY | INSYS Therapeutics, Inc |
N/A |
USD4,995,459.82B | 115.90 | N/A |
| CHKE | Apex Global Brands Inc |
N/A |
USD384,202.91B | 17.30 | N/A |
| AMCN | AirNet Technology Inc |
N/A |
USD308,457.30B | 1.00 | N/A |
| PDVW | pdvWireless, Inc |
N/A |
USD95,944.74B | N/A | N/A |
| AIPT | Predictive Oncology Inc |
N/A |
USD38,513.36B | N/A | N/A |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|
N/A
| Market Performance vs. Industry/Classification (Other) |
Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Trailing 12 Months | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Trailing 5 Years | |||||||
| Capital Gain | 692.28% | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 692.28% | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 50.00% | N/A | N/A | N/A | N/A | ||
| Dividend Return | -6.91% | N/A | N/A | N/A | N/A | ||
| Total Return | 43.09% | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 143.90% | N/A | N/A | N/A | N/A | ||
| Risk Adjusted Return | 29.95% | N/A | N/A | N/A | N/A | ||
| Market Capitalization | 1.07B | N/A | N/A | N/A | N/A | ||
| Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
| A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
| B+ | 87%-89% | B | 83%-86% | B- | 80%-82% |
| C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
| D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
| F | 0%-59% |
| Ratio vs. Industry/Classification (Other) |
Ratio vs. Market |
||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| Market Value | |||||||
| Price / Earning Ratio | N/A | N/A | N/A | N/A | N/A | ||
| Price/Book Ratio | 2.13 | N/A | N/A | N/A | N/A | ||
| Price / Cash Flow Ratio | 5.99 | N/A | N/A | N/A | N/A | ||
| EV/EBITDA | 10.16 | N/A | N/A | N/A | N/A | ||
| Management Effectiveness | |||||||
| Return on Equity | -0.08% | N/A | N/A | N/A | N/A | ||
| Return on Invested Capital | 54.95% | N/A | N/A | N/A | N/A | ||
| Return on Assets | 2.81% | N/A | N/A | N/A | N/A | ||
| Debt to Equity Ratio | 264.42% | N/A | N/A | N/A | N/A | ||
| Technical Ratios | |||||||
| Short Ratio | 3.52 | N/A | N/A | N/A | N/A | ||
| Short Percent | 1.16% | N/A | N/A | N/A | N/A | ||
| Beta | 1.98 | N/A | N/A | N/A | N/A | ||
| Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
| A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
| B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
| C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
| D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
| F | 0%-59% |
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
No discussions yet
| User Name | Target Rating | Target Horizon (Months) | Target Price | User Analysis | Date | Comment |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
There is nothing we particularly dislike
Do not have an account? Register here
